Format

Send to

Choose Destination
J Autism Dev Disord. 2011 May;41(5):545-54. doi: 10.1007/s10803-010-1078-8.

A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder.

Author information

1
Osher Center for Integrative Medicine, Department of Medicine, University of California, San Francisco VAMC, 111-A1, 4150 Clement St., San Francisco, CA 94121, USA. Stephen.Bent@ucsf.edu

Abstract

We conducted a pilot randomized controlled trial to determine the feasibility and initial safety and efficacy of omega-3 fatty acids (1.3 g/day) for the treatment of hyperactivity in 27 children ages 3-8 with autism spectrum disorder (ASD). After 12 weeks, hyperactivity, as measured by the Aberrant Behavior Checklist, improved 2.7 (± 4.8) points in the omega-3 group compared to 0.3 (± 7.2) points in the placebo group (p = 0.40; effect size = 0.38). Correlations were found between decreases in five fatty acid levels and decreases in hyperactivity, and the treatment was well tolerated. Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00786799.

PMID:
20683766
PMCID:
PMC3076562
DOI:
10.1007/s10803-010-1078-8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center